Literature DB >> 14668977

The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys.

Zuzana Justinova1, Gianluigi Tanda, Patrik Munzar, Steven R Goldberg.   

Abstract

RATIONALE: Experimental evidence from animal studies suggests reciprocal functional interactions between endogenous brain cannabinoid and opioid systems. There is recent evidence for a role of the opioid system in the modulation of the reinforcing effects of synthetic cannabinoid CB1 receptor agonists in rodents. Since Delta(9)-tetrahydrocannabinol (THC), the natural psychoactive ingredient in marijuana, is actively and persistently self-administered by squirrel monkeys, this provides an opportunity to directly study involvement of opioid systems in the reinforcing effects of THC in non-human primates.
OBJECTIVES: To study the effects of naltrexone, an opioid antagonist, on THC self-administration behavior in squirrel monkeys.
METHODS: Monkeys pressed a lever for intravenous injections of THC under a ten-response, fixed-ratio (FR) schedule with a 60-s time-out after each injection. Effects of pre-session treatment with naltrexone (0.03-0.3 mg/kg intramuscularly, 15 min before session) for 5 consecutive days on self-administration of different doses of THC (2-8 microg/kg per injection) were studied.
RESULTS: Self-administration responding for THC was significantly reduced by pretreatment with 0.1 mg/kg naltrexone for five consecutive daily sessions. Naltrexone pretreatment had no significant effect on cocaine self-administration responding under identical conditions.
CONCLUSIONS: Self-administration behavior under a fixed-ratio schedule of intravenous THC injection was markedly reduced by daily pre-session treatment with naltrexone, but remained above saline self-administration levels. These findings demonstrate for the first time the modulation of the reinforcing effects of THC by an opioid antagonist in a non-human primate model of marijuana abuse.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14668977     DOI: 10.1007/s00213-003-1693-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  51 in total

1.  Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus.

Authors:  J J Rodriguez; K Mackie; V M Pickel
Journal:  J Neurosci       Date:  2001-02-01       Impact factor: 6.167

2.  Functional interaction between opioid and cannabinoid receptors in drug self-administration.

Authors:  M Navarro; M R Carrera; W Fratta; O Valverde; G Cossu; L Fattore; J A Chowen; R Gomez; I del Arco; M A Villanua; R Maldonado; G F Koob; F Rodriguez de Fonseca
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

3.  Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys.

Authors:  M C Ko; E R Butelman; J R Traynor; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

4.  Naloxone antagonizes GABA(A)/benzodiazepine receptor function in rat corticohippocampal synaptoneurosomes.

Authors:  A I Svensson; A Berntsson; M Eirefelt; B Söderpalm
Journal:  J Neural Transm (Vienna)       Date:  2000       Impact factor: 3.575

5.  Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.

Authors:  G Tanda; F E Pontieri; G Di Chiara
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

Review 6.  The cannabinoid receptors.

Authors:  Allyn C Howlett
Journal:  Prostaglandins Other Lipid Mediat       Date:  2002-08       Impact factor: 3.072

7.  Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system.

Authors:  D Braida; M Pozzi; R Cavallini; M Sala
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

8.  Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats.

Authors:  Taco J De Vries; Judith R Homberg; Rob Binnekade; Halfdan Raasø; Anton N M Schoffelmeer
Journal:  Psychopharmacology (Berl)       Date:  2003-04-01       Impact factor: 4.530

9.  Naloxone attenuation of the effect of cocaine on rewarding brain stimulation.

Authors:  G T Bain; C Kornetsky
Journal:  Life Sci       Date:  1987-03-16       Impact factor: 5.037

10.  Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study.

Authors:  M Herkenham; A B Lynn; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  J Neurosci       Date:  1991-02       Impact factor: 6.167

View more
  47 in total

Review 1.  Clinical safety of 1500 mg oral naltrexone overdose.

Authors:  Albert Stuart Reece
Journal:  BMJ Case Rep       Date:  2010-09-07

Review 2.  Animal models of cannabinoid reward.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 3.  Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines.

Authors:  Christopher D Rosenbaum; Stephanie P Carreiro; Kavita M Babu
Journal:  J Med Toxicol       Date:  2012-03

4.  Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats.

Authors:  Marcello Solinas; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

Review 5.  [Future medications for tobacco and cannabis dependence].

Authors:  Bernard Le Foll; Zuzana Justinova; Gianlugi Tanda; Steven R Goldberg
Journal:  Bull Acad Natl Med       Date:  2008-01       Impact factor: 0.144

Review 6.  Looking for the role of cannabinoid receptor heteromers in striatal function.

Authors:  Sergi Ferré; Steven R Goldberg; Carme Lluis; Rafael Franco
Journal:  Neuropharmacology       Date:  2008-07-19       Impact factor: 5.250

7.  Novel Pharmacologic Approaches to Treating Cannabis Use Disorder.

Authors:  Rebecca E Balter; Ziva D Cooper; Margaret Haney
Journal:  Curr Addict Rep       Date:  2014-06-01

Review 8.  Screening Medications for the Treatment of Cannabis Use Disorder.

Authors:  L V Panlilio; Z Justinova; J M Trigo; B Le Foll
Journal:  Int Rev Neurobiol       Date:  2016-03-10       Impact factor: 3.230

Review 9.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

10.  Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates.

Authors:  Zuzana Justinova; Regina A Mangieri; Marco Bortolato; Svetlana I Chefer; Alexey G Mukhin; Jason R Clapper; Alvin R King; Godfrey H Redhi; Sevil Yasar; Daniele Piomelli; Steven R Goldberg
Journal:  Biol Psychiatry       Date:  2008-09-23       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.